Receptor-interacting protein 1 kinase (RIPK1) inhibitors are emerging as a new pharmacological class proposed for inflammatory, autoimmune, and neurodegenerative diseases such as rheumatoid arthritis, ulcerative colitis, psoriasis, Alzeihmer disease, amyotrophic lateral sclerosis, or multiple sclerosis [1,2,3,4]. Here, RIPK1 is linked to ulcerative colitis.